🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#AACR25 RAF/MEK clamp avutometinib combined with a pan-RAF inhibitor induces nearly complete MAPK pathway inhibition with deep tumor regressions in NRAS or BRAF class III mutant models ▪️ verastem.com/pdf/AACR-Avuto…

#AACR25 VS-7375 (GFH375): An oral, selective KRAS G12D (ON/OFF) inhibitor with potent anti-tumor efficacy as single agent and in combination with other anticancer therapies in preclinical models. ▪️ VS-7375 shows improved KRAS G12D selectivity and potency vs other KRAS G12D

Highly significant selection of the first speaker in the opening plenary at #AACR25: Kevan Shokat talking about the impressive progress in targeting KRas with small molecules. Decades of investing into fundamental science now generating first clinical impact. And much more to come…

#AACR25 Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors

☦️ Habemus Papam! @drprevost

🎉 🎯 FDA Oncology Approves the AVMAPKI™ FAKZYNJA™ (avutometinib/defactinib) Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer #LGSOC. “I am proud of the many firsts this registration brings

Fantastic #PDAC early data ASCO #ASCO25!! Dose level 1 demonstrated an ORR of 83% (10/12) in frontline metastatic pancreatic ductal adenocarcinoma Plans for registrational Phase 3 study underway in frontline metastatic pancreatic ductal adenocarcinoma • RAMP 205 Evaluating

FAK: Fearless Ambition, Kinase Victory PYK2: Persevere, Yield to Knowledge, 2 Triumph. • Finally figured it out, what defactinib stands for!! 😉 Time for FAK to shine!! Now, also, FDA Oncology approved in LGSOC #ovarian indication!! Christoph Westphal Anirban Maitra Vivek Subbiah, MD #ASCO25 pic.x.com/bE4PlDAuAQ

👏 🇭🇷 🇪🇸 ⚽️

👏

🚨🥁Hot off the press 👉ASCO #ASCO25 Delighted to share with the 🌎my commentary in Nature Communications perfectly timed for #ASCO25! 👉"Tissue-agnostic cancer therapies: promise, reality, and the path forward" 👉Diving deep into where we are & where we're headed with these

"Informative censoring will no longer be a dry concept, you'll be able to visualize it live!" #BreakingIce #ASCO25 Vivek Subbiah, MD Arndt Vogel Yüksel Ürün Razelle Kurzrock, MD Stephen V Liu, MD Marty Makary MD, MPH ONCO BRUNO Bruna Pellini, MD Christian Rolfo Rami Manochakian MD, FASCO Cancer Education Sanjay Popat

Updated, expanded RAMP205 data #ASCO25 for avutometinib(RAF/MEK clamp)/ defactinib (FAKi) combo with gemcitabine and Nab-paclitaxel. Impressive data!! 🔸️Dose level 1 demonstrated an ORR of 83% (10/12), 100% DCR in frontline metastatic pancreatic ductal adenocarcinoma 🔸️Plans

“Offer me money. Offer me power. I don’t care. I’ll say what I want to say and if the consequence of that is losing money so be it.” — Elon Musk

War does not solve problems; on the contrary, it amplifies them and inflicts deep wounds on the history of peoples, which take generations to heal. No armed victory can compensate for the pain of mothers, the fear of children, or stolen futures. May diplomacy silence the weapons!